Scholarlink

<p>With the implementation of immunotherapy, a completely new, broad spectrum of side effects has emerged in oncology—the immune-related adverse events (irAEs). Their management differs greatly from that of classic cytotoxic side effects and is based primarily on corticosteroids, immunomodulatory agents, and treatment interruptions. Whereas some events are low grade and reversible, others can be severe and lead to permanent disorders or even death. Therefore, early recognition and treatment in the context of interdisciplinary side effects management is critical for patients’ safety, prognosis, and quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nebenwirkungsmanagement unter Immuntherapie

  • 期刊论文

  • 发表日期：

    2025年2月11日

查看全文
  • Marika Henriette Princk,
  • Mascha Pervan,
  • Jörg Riedl

摘要

With the implementation of immunotherapy, a completely new, broad spectrum of side effects has emerged in oncology—the immune-related adverse events (irAEs). Their management differs greatly from that of classic cytotoxic side effects and is based primarily on corticosteroids, immunomodulatory agents, and treatment interruptions. Whereas some events are low grade and reversible, others can be severe and lead to permanent disorders or even death. Therefore, early recognition and treatment in the context of interdisciplinary side effects management is critical for patients’ safety, prognosis, and quality of life.